Form 4 for BBNX Beta Bionics, Inc.
Accepted 2025-02-03 00:00:00 ET · period of report 2025-01-31 · accession 0001415889-25-002819 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2025-02-03 | 2025-01-31 | BBNX | Mensinger Mike | Chief Product Off | C - Cnv Deriv | — | +15.1K | 15.1K | New | — |
| D | 2025-02-03 | 2025-01-31 | BBNX | Mensinger Mike | Chief Product Off | P - Purchase | $17.00 | +33.4K | 59.0K | +130% | +$567.0K |
| D | 2025-02-03 | 2025-01-31 | BBNX | Mensinger Mike | Chief Product Off | S - Sale+OE | $17.00 | -13 | 25.7K | -0.1% | -$221 |
| D | 2025-02-03 | 2025-01-31 | BBNX | Mensinger Mike | Chief Product Off | X - OptEx | $0.02 | +10.6K | 25.7K | +70% | +$211.50 |
| DM | 2025-02-03 | 2025-01-31 | BBNX | Mensinger Mike | Chief Product Off | A - Grant | $0.00 | +346.8K | 236.6K | New | $0 |
| D | 2025-02-03 | 2025-01-31 | BBNX | Mensinger Mike | Chief Product Off | X - OptEx | $0.00 | -10.6K | 0 | -100% | $0 |
| DM | 2025-02-03 | 2025-01-31 | BBNX | Mensinger Mike | Chief Product Off | C - Cnv Deriv | $0.00 | -4,532 | 10.6K | -30% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-01-31 | C | A | 15,107 | — | 15,107 | D | — | — | (F1) Immediately prior to the closing of the initial public offering, each share of Series D Preferred Stock (the "Preferred Stock") was converted into an equal number of shares of Class B Common Stock and subsequently was converted into an equal number of shares of Common Stock without payment of further consideration. The Preferred Stock had no expiration date. |
| 2 | Common | Common Stock | 2025-01-31 | P | A | 33,350 | $17.00 | 59,019 | D | — | — | |
| 3 | Common | Common Stock | 2025-01-31 | S | D | 13 | $17.00 | 25,669 | D | — | — | |
| 4 | Common | Common Stock | 2025-01-31 | X | A | 10,575 | $0.02 | 25,682 | D | — | — | |
| 5 | Derivative | Employee Stock Option (right to buy) | 2025-01-31 | A | A | 110,278 | $0.00 | 110,278 | D | $17.00 · — to 2025-01-28 | 110,278 Common Stock | (F7) Vesting is monthly over a 48-month period starting January 29, 2025 in equal monthly amounts. |
| 6 | Derivative | Employee Stock Option (right to buy) | 2025-01-31 | A | A | 236,553 | $0.00 | 236,553 | D | $5.10 · — to 2033-09-13 | 236,553 Common Stock | (F5) One-fourth of the shares subject to this option shall vest one year after August 1, 2023, and thereafter 1/36th of the shares subject to this option shall vest on each monthly anniversary thereof. |
| 7 | Derivative | Class B Common Stock Warrant (right to buy) | 2025-01-31 | X | D | 10,575 | $0.00 | 0 | D | $0.02 · 2023-08-28 to 2033-08-27 | 10,575 Common Stock | |
| 8 | Derivative | Series D Preferred Stock | 2025-01-31 | C | D | 15,107 | — | 0 | D | — · — to — | 15,107 Common Stock | (F1) Immediately prior to the closing of the initial public offering, each share of Series D Preferred Stock (the "Preferred Stock") was converted into an equal number of shares of Class B Common Stock and subsequently was converted into an equal number of shares of Common Stock without payment of further consideration. The Preferred Stock had no expiration date. |
| 9 | Derivative | Class B Common Stock Warrant (right to buy) | 2025-01-31 | C | A | 10,575 | $0.00 | 10,575 | D | $0.02 · 2023-08-28 to 2033-08-27 | 10,575 Common Stock |